Interleukin-2 and systemic lupus erythematosus - Fifteen years later

Lupus

Volumn 7, Issue 4, 1998, Pages 214-222

  Crispin, J C ^a   Alcocer Varela, J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Autoimmunity; Cytokines; Interleukin 2; Systemic lupus erythematosus

Indexed keywords

CYTOKINE; INTERLEUKIN 2;

ARTICLE; AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; HUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AUTOIMMUNITY; HUMANS; INTERLEUKIN-2; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0031778158     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678920028     Document Type: Article

References (96)

1. Brandhuber BJ, Boone T, Kenney WC, McKay DB. Three-dimensional structure of IL-2. Science 1987; 238: 1707-1709.
2. Fishbein E, Alcocer-Varela J, Alarcón-Segovia D. Cellular bases of the production of and response to interleukin-2 in man: role of autologous rosette-forming T-cell subsets defined with monoclonal antibodies. Immunology 1983; 50: 223-227.
3. Carson WE, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180: 1395-1403.
4. Paul WE. Fundamental immunology (3rd edn). Raven Press: New York, 1993.
5. Fraser JD, Straus D, Weiss A. Signal transduction events leading to T-cell lymphokine gene expression Immunol Today 1993; 14: 357-362.
6. Ullman KS, Northrop JP, Verweij CL, Crabtree GR. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function. The missing link Annu Rev Immunol 1990; 8: 421-452.
7. Cantrell DA, Smith KA. Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med 1983; 158: 1895-1911.
8. Kroemer G, et al. Interleukm-2, autotolerance and autoimmunity Adv Immunol 1991; 50: 147-235.
9. Kroemer G, Martinez-A C. Cytokines and autoimmune disease. Clin Immunol Immunopathol 1991; 61: 275-295.
10. Alarcón-Segovia D, Alcocer-Varela J, Diaz-Jouanen E. The connective tissue diseases as disorders of immune regulation. Clin Rheum Dis 1985; 11: 451-469.
11. Via CS, Handwerger BS B-cell and T-cell function in systemic lupus erythematosus. Curr Opin Rheumatol 1993; 5: 570-574.
12. Sadlack B, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995; 25: 3053-3059.
13. Horak I, Löhler J, Ma A, Smith KA. Interleukin-2 deficient mice: A new model to study autoimmunity and self-tolerance. Immunol Rev 1995; 148: 35-44.
14. Wang R, Rogers AM, Rush BJ, Russell JH. Induction of sensitivity to activation-induced death in primary CD4+ cells: a role for interleukin-2 in the negative regulation of responses by mature CD4+ T cells. Eur J Immunol 1996; 26: 2263-2270
15. Klebb G, et al. Interleukin-2 is indispensable for development of imrminological self-tolerance. Clm Immunol Immunopathol 1996; 81: 282-286.
16. Mor F, Cohen IR. IL-2 rescues antigen-specific T cells from radiation of dexamethasone-induced apoptosis. Correlation with induction of bcl-2. J Immunol 1996; 156: 515-522.
17. Mountz JD, Cause WC. Murine models of autoimmune disease and Sjögren's syndrome. Curr Opin Rheumatol 1993; 5: 557-569.
18. Gutierrez-Ramos JC, et al. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukm-2/vaccinia recombinant virus. Nature 1990; 346: 271-274.
19. Raz E, et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-292.
20. Gutierrez-Ramos JC, Moreno de Alboran I, Martinez-A C. In vivo administration of interleukin-2 turns on anergic self-reactive T cells and leads to autoimmune disease. Eur J Immunol 1992; 22: 2867-2872.
21. Sakaguchi S, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). J Immunol 1995; 155: 1151-1164
22. Taguchi O, Takahashi T. Administration of anti-interleukin-2 receptor α antibody in vivo induces localized autoimmune disease. Eur J Immunol 1996; 26: 1608-1616.
23. Wofsy D, et al Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the Ipr gene. J Exp Med 1981; 154: 1671-1680.
24. Altman A, et al. Analysis of T cell function in autoimmune murine strains. Defects in production of and responsiveness to interleukin 2. J Exp Med 1981; 154: 791-808.
25. Dauphinée MJ, Kipper SB, Wofsy D, Talal N Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 1981; 127: 2483-2487.
26. Yoshii H, et al. Age-related differential mRNA expression of T cell cytokines in NZB/NZW F1 mice. Lupus 1995; 4: 213-216.
27. Sekigawa I, et al. B cell hyperresponsiveness to interleukin 2 and the age-associated decline in murine lupus. Clin Immunol Immunopathol 1989; 51: 172-184.
28. Horwitz DA, Garrett MA. Lymphocyte reactivity to mitogens in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Clin Exp Immunol 1977; 27: 92-99.
29. Alcocer-Varela J, Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982; 69: 1388-1392.
30. Linker-Israeli M, et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130: 2651-2655.
31. Miyasaka N, Nakamura T, Russell IJ, Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 1984; 31: 109-117.
32. Warrington RJ. Interleukin-2 abnormalities in systemic lupus erythematosus and rheumatoid arthritis. A role for overproduction of interleukin-2 in human autoimmunity? J Rheumatol 1988; 15: 616-620.
33. Murakawa Y, et al. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematous. J Immunol 1985; 134: 187-195.
34. Linker-Israeli M, Bakke AC, Quismorio FP, Horwitz DA. Correction of interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells. J Clin Invest 1985; 75. 762-768.
35. 8 T cells: their activation and effector functions. Curr Opin Immunol 1994; 6: 453-457.
36. Huang Y-P, Miescher PA, Zubler RH. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol 1986; 137: 3515-3520.
37. Warrington RJ, Sauder PJ, Homik J, Ofosu-Appiah W. Reversible interleukin-2 response defects in systemic lupus erythematosus. Clin Exp Immunol 1989; 77: 163-167.
38. Santoro TJ, et al. In vitro correction of the interleukin 2 defect of autoimmune mice. Eur J Immunol 1983; 13: 601-604.
39. Hayama T, et al. Functional T cell subpopulations responsible for hyposecretion of IL-2 in patients with systemic lupus erythematosus. Clin Rheumatol 1991; 10: 388-394.
40. Murakawa Y, Sakane T. Deficient phytohemagglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate. Arthritis Rheum 1988; 31: 826-833.
41. Sicrakowski S, Kucharz EJ, Lightfoot RW, Goodwin JS. Impaired T-cell activation in patients with systemic lupus erythematosus. J Clin Immunol 1989; 9: 469-476.
42. Sibbitt W, et al. Lymphokines in autoimmunity: relationship between interleukin-2 and interferon-γ production in systemic lupus erythematosus. Clin Immunol Immunopathol 1984; 32: 166-173.
43. Tada Y, et al. A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1991; 60: 220-231.
44. García-Cózar FJ, et al. Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 1996; 104: 72-79.
45. Umlauf SW, et al. Molecular regulation of the IL-2 gene: Rheostatic control of the immunc system. Immunol Rev 1993; 133: 177-197.
46. Alvarado C, et al. Effect of CD28 antibody on T cells from patients with systemic lupus erythematosus. J Autoimmunity 1994; 7: 763-773.
47. Becker H, Stengl G, Stein M, Federlin K. Analysis of proteins that interact with the IL-2 regulatory region in patients with rheumatoid diseases. Clin Exp Immunol 1995; 99: 325-330.
48. Rosenberg YJ, Steinberg AD, Santoro TJ. The basis of autoimmunity in MRL-lpr/lpr mice: a role for self Ia-reactive T cells. Immunol Today 1984; 5: 64-67.
49. Cuadrado MJ, et al. Relationship of IL-2, IL-2R (CD25), soluble IL-2R and IL-4 with disease activity in SLE patients. Lupus 1993; 2: 257-260.
50. Linker-Israeli M, Deans R. Dysregulated lymphokine production in systemic lupus erythematosus (SLE). Ann N Y Acad Sci 1989; 557: 567-569.
51. Horwitz DA, Wang H, Gray JD. Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosus: Increased interleukin-2 but not interleukin-4 mRNA. Lupus 1994; 3: 423-428.
52. Richaud-Patin Y, Alcocer-Varela J, Llorente L. High levels of Th2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin 1995, 47: 267-272.
53. Barcellini W, et al. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus. lack of relationship with clinical disease activity. Lupus 1996; 5: 139-145.
54. Sakane T, et al. Familial occurrence of impaired interleukin-2 activity and increased peripheral blood B cells actively secreting immunoglobulins in systemic lupus erythematosus. Am J Med 1989; 86: 385-390.
55. Huang Y-P, Perrin LH, Miescher PA, Zubler RH Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1988; 141: 827-833.
56. Alcocer-Varela J, Alarcón-Segovia D. Longitudinal study on the production of and cellular response to interleukin-2 in patients with systemic lupus erythematosus. Rheumatol Int 1995; 15: 57-63.
57. Alcocer-Varela J, et al Activation markers on peripheral blood T cells from patients with active or inactive systemic lupus erythematosus. Correlation with proliferative responses and production of IL-2. J Autoimmunity 1991; 4: 935-945.
58. Klinman DM, et al. Oncogene expression in autoimmune and normal peripheral blood mononuclear cells. J Exp Med 1986; 163: 1292-1307.
59. Lorenz HM, et al. In vitro apoptosis and expression of apoptosisrelated molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases Arthritis Rheum 1997; 40: 306-317.
60. Hishikawa T, et al. HLA-DP+ T cells and deficient interleukin-2 production in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1990; 55: 285-296.
61. Talal N, Dauphinee MJ, Wofsy D. Interleukin-2 deficiency, genes and systemic lupus erythematosus. Arthritis Rheum 1982; 25: 838-842.
62. Suzuki T, et al. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995; 99: 251-255.
63. Tanaka T, et al. Decreased expression of interleukin-2 binding molecules (p70/75) in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 552-559.
64. Martínez OM, Gibbons RS, Garovoy MR, Aronson FR. IL-4 inhibits IL-2 receptor expression and IL-2 dependent proliferation of human T cells J Immunol 1990; 144: 2211-2215.
65. Tomizawa K, et al. Interleukin-4 regulates the interleukin-2 receptors on human peripheral blood B lymphocytes. Clin Exp Immunol 1991; 83: 492-496.
66. Wigfall DR, Sakai RS, Wallace DJ, Jordan SC. Interleukin -2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: Relationship to clinical activity. Clin Immunol Immunopathol 1988; 47: 354-362.
67. Ishida H, et al. Impaired expression of high affinity interleukin 2 receptors on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol 1987; 139: 1070-1074.
68. Robin LA, Nelson DL. The soluble interleukin-2 receptor, biology, function and clinical application. Ann Intern Med 1990; 113: 619-627.
69. Manoussakis MN, Papadopoulos GK, Drosos AA, Moutsopoulos HM. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol 1989; 50: 321-332.
70. Wolf RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988; 31: 729-735.
71. Gilad R, et al. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol 1997; 36: 190-193.
72. Kucharz EJ, Goodwin JS. Serum inhibitors of interleukin-2 Life Sci 1988; 42: 1485-1491.
73. Miyagi J, et al Two types of antibodies inhibiting interleukin-2 production by normal lymphocytes in patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1356-1364.
74. Sano H. el al. Systemic lupus erythematosus sera antilymphocyte reactivity: detection of antibodies to Tac-antigen positive T cell lines. Clin Exp Immunol 1986; 63: 8-16.
75. Honda M, Chan C, Shevach EM Characterization and partial purification of a specific interleukin 2 inhibitor. J Immunol 1985; 135: 1834-1839.
76. Djeu JY, Kasahara T, Balow JE, Tsokos GC. Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders. Clin Exp Immunol 1986; 65: 279-285.
77. Lattime EC, Gillis S, David C, Stutman O. Interleukin 2, production in the syngeneic mixed lymphocyte reaction. Eur J Immunol 1981; 11: 67-69.
78. Smith JB, Talal N. Significance of self-recognition and interleukin-2 for immunoregulation, autoimmunity and cancer. Scand J Immunol 1982; 16: 269-278.
79. Takada S, et al. Abnormalities in autologous mixed lymphocyte reaction-activated immunologic processes in systemic lupus erythematosus and their possible correction by interleukin-2. Eur J Immunol 1985; 15: 262-267.
80. Laffón A, Alcocer-Varela J, Alarcón-Segovia D. Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases. Rheumatol Int 1983; 3: 117-128.
81. Kuntz MM, Innes JB, Weksler ME. The cellular basis of the impaired autologous mixed lymphocyte reaction in patients with systemic lupus erythematosus. J Clin Invest 1979; 63: 151-153.
82. Sakane T, Steinberg AD, Green I. Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1978; 75: 3464-3468.
83. Via CS, et al. T cell-antigen-presentmg cell interactions in human systemic lupus erythematosus. J Immunol 1993; 151: 3914-3922.
84. Alcocer-Varela J, Laffón A, Alarcón-Segovia D. Defective monocyte production of, and T lymphocyte response to, interleukin-1 in the peripheral blood of patients with systemic lupus erythematosus. Clin Exp Immunol 1983; 54: 125-132
85. Tsokos GC, et al. Defective antigen-presenting cell function in patients with systemic lupus erythematosus. Role of the B7-1 (CD80) costimulatory molecule Arthritis Rheum 1996; 39: 600-609.
86. Chouaib S, Fradelizi D. The mechanism of inhibition of human IL-2 production. J Immunol 1982; 129: 2463-2468.
87. 2 effects on human suppressor cell function and on interleukin 2 function. J Immunol 1982; 129: 2469-2473.
88. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 1992; 63: 10-12.
89. Martínez-Cordero E, Alcocer-Varela J, Alarcón-Segovia D. Stimulating and differentiation factors for human B lymphocytes in systemic lupus erythematosus. Clin Exp Immunol 1986; 65: 598-604.
90. Llorente L, el al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993; 4: 412-430.
91. Hagiwara E, Gourley MF, Lee S, Klinman DM. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-γ-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-385.
92. Llorente L, et al Dysregulation of interleukin 10 prouuction in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1429-1435.
93. Llorente L, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-844.
94. Richaud-Patin Y, Alvarado C, Villaseñor-Bustamante S, Llorente L. Role of interleukin-10 in autoimmunity; physiological and pathological implications. Rev Bras Rheumatol 1997; 37: 159-164.
95. Schlaak JF, et al. Differential effects of IL-10 on proliferation and cytokine production of human γ/δ and α/β T cells Scand J Immunol 1994, 39: 209-215.
96. de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4-I- T cell clones and resting T cells. J Immunol 1993, 150: 4754-4765.